The present invention relates to compounds of formula (I), wherein R.sup.1 to R.sup.3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

The present invention relates to a novel compound, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of refractory cancer, comprising the novel compound or a pharmaceutically acceptable salt thereof. When the composition of the present invention and anticancer drug are administered in combination, excellent anticancer effects can be exhibited.

The present invention relates to a novel compound, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of refractory cancer, comprising the novel compound or a pharmaceutically acceptable salt thereof. When the composition of the present invention and anticancer drug are administered in combination, excellent anticancer effects can be exhibited.

Disclosed are a tri-heterocyclic compound as a JAK inhibitor, and the use thereof in the preparation of a drug for treating JAK1- or/and JAK2-related diseases. Specifically, the present invention relates to a compound as shown in formula (I′) or a pharmaceutically acceptable salt thereof.

##STR00001##

The present invention provides a luminescent film containing at least a phosphorescent compound and a fluorescent compound, wherein the convolution integral value J of the emission spectrum of the phosphorescent compound and the absorption spectrum of the fluorescent compound satisfies equation (1), the light emission from the fluorescent compound accounts for at least 90% of the emission spectrum of the luminescent film, and the absolute photoluminescence quantum efficiency (PLQE) of the luminescent film is represented by equation (2). Equation (1): J≥1.5×10.sup.14, Equation (2): PLQE (a film composed of a phosphorescent compound and a host compound)×0.9≤PLQE (a film containing a phosphorescent compound and a fluorescent compound) [The lowest triplet excited state of the host compound is higher than the lowest triplet excited state of the phosphorescent compound, and does not suppress the luminescent property of the phosphorescent compound.]

The present invention belongs to the technical field of medicines, and particularly relates to a method for synthesizing an anti-tumor compound and intermediates thereof. The synthesis method of the present invention has improved operability and allows for a simplified process, in which higher purity can be achieved without the complicated process of recrystallizing the synthesized target compound, and thus less of the three wastes is produced, making the method more suitable for industrial mass production. Where the intermediates according to the present invention are used for preparing an anti-tumor compound, by-products are effectively reduced during reactions, and thus the overall yield of the reactions are improved, and is at least twice as high as that obtained using the existing synthesis method.

The present invention belongs to the technical field of medicines, and particularly relates to a method for synthesizing an anti-tumor compound and intermediates thereof. The synthesis method of the present invention has improved operability and allows for a simplified process, in which higher purity can be achieved without the complicated process of recrystallizing the synthesized target compound, and thus less of the three wastes is produced, making the method more suitable for industrial mass production. Where the intermediates according to the present invention are used for preparing an anti-tumor compound, by-products are effectively reduced during reactions, and thus the overall yield of the reactions are improved, and is at least twice as high as that obtained using the existing synthesis method.

Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.

Disclosed are a kind of fused ring derivatives, and specifically disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

##STR00001##

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: ##STR00001##
or a pharmaceutically acceptable salt or prodrug thereof, wherein A.sub.1-A.sub.3, B.sub.1-B.sub.3, D.sub.1-D.sub.4 and R.sub.1-R.sub.2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.